Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Revenue (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Revenue for 5 consecutive years, with $10.0 million as the latest value for Q3 2025.

  • Quarterly Revenue rose 2177.9% to $10.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, down 5.55% year-over-year, with the annual reading at $10.0 million for FY2025, 5.55% down from the prior year.
  • Revenue for Q3 2025 was $10.0 million at Janux Therapeutics, up from $439000.0 in the prior quarter.
  • The five-year high for Revenue was $10.0 million in Q3 2025, with the low at $380000.0 in Q1 2021.
  • Average Revenue over 5 years is $2.6 million, with a median of $1.7 million recorded in 2021.
  • The sharpest move saw Revenue tumbled 82.56% in 2024, then surged 2177.9% in 2025.
  • Over 5 years, Revenue stood at $1.6 million in 2021, then soared by 76.05% to $2.8 million in 2022, then dropped by 13.5% to $2.5 million in 2023, then plummeted by 82.16% to $439000.0 in 2024, then soared by 2177.9% to $10.0 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $10.0 million, $439000.0, and $8.9 million for Q3 2025, Q3 2024, and Q2 2024 respectively.